Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $11.17.
SLRN has been the subject of several analyst reports. Piper Sandler dropped their price objective on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Morgan Stanley decreased their target price on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Monday, August 19th. HC Wainwright lowered shares of Acelyrin from a “buy” rating to a “neutral” rating and decreased their target price for the company from $18.00 to $6.00 in a report on Wednesday, August 14th. Finally, Wells Fargo & Company raised their target price on shares of Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, October 16th.
Check Out Our Latest Stock Analysis on Acelyrin
Institutional Investors Weigh In On Acelyrin
Acelyrin Stock Down 7.8 %
Shares of Acelyrin stock opened at $5.90 on Monday. Acelyrin has a twelve month low of $3.36 and a twelve month high of $10.50. The company has a 50-day simple moving average of $5.16 and a two-hundred day simple moving average of $4.94. The stock has a market capitalization of $584.26 million, a price-to-earnings ratio of -2.48 and a beta of 2.33.
Acelyrin (NASDAQ:SLRN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same period last year, the business posted ($0.56) EPS. On average, sell-side analysts anticipate that Acelyrin will post -3.08 earnings per share for the current fiscal year.
Acelyrin Company Profile
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured Articles
- Five stocks we like better than Acelyrin
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Compound Interest and Why It Matters When Investing
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.